This PubMed entry describes a prespecified secondary analysis from the SELECT randomized controlled trial that evaluated the effect of Semaglutide on the inflammatory biomarker high-sensitivity CRP (hs-CRP) in patients with established cardiovascular disease and overweight or obesity. The article title explicitly frames the analysis as prespecified and focused on hs-CRP in the SELECT population.
The source document available here is the PubMed record and associated metadata; the provided excerpt does not contain the abstract text or detailed narrative of the study background, rationale, or hypotheses. Therefore, specific background context beyond the title and study focus is not reported in the source and cannot be inferred here.
The PubMed entry classifies the work as a Randomized Controlled Trial and identifies the content as a prespecified secondary analysis from the SELECT trial. Beyond this classification, the source excerpt does not report the trial's detailed design elements: sample size, randomization specifics, semaglutide dosing regimen, comparator, duration of follow-up, inclusion and exclusion criteria, timing and methods of hs-CRP measurement, statistical analysis plan, or predefined endpoints for this secondary analysis. Those methodological details were not included in the excerpt and therefore are not reported here.
The article lists multiple authors led by Jorge Plutzky with many international collaborators. The PubMed excerpt provides a full author list with numbered affiliations. Key affiliations reported include:
The author list in the PubMed entry includes specific investigator names and institutional affiliations as reported, and these are provided above exactly as listed in the source. The excerpt does not include conflicts of interest beyond the standard PubMed navigation headings; any conflict-of-interest disclosures in the full text are not reported here.
The PubMed record reports the bibliographic citation and indexing details as follows:
These identifiers are provided in the source metadata and can be used to access the full manuscript for complete methods, results, and author conclusions.
The provided PubMed excerpt documents the article title, author list, affiliations, bibliographic identifiers, article type, and links to full text. However, the excerpt does not include the abstract body or the numerical and statistical results of the prespecified secondary analysis. Specifically, the following items were not reported in the provided source excerpt and thus cannot be summarized here:
Because these outcome and method details are absent from the PubMed excerpt supplied, they are explicitly noted as not reported here. To obtain these data, consult the full-text article via the DOI/publisher link noted in the PubMed record.
Based on the PubMed metadata alone, clinicians and researchers can note that a prespecified secondary analysis addressing the effect of Semaglutide on high-sensitivity CRP in a population with established cardiovascular disease and overweight or obesity has been published in a major cardiovascular journal (Circulation). The full clinical and statistical implications of the analysis — including whether semaglutide reduced hs-CRP and the magnitude and significance of any effect — are not available in the provided excerpt.
Recommended next steps for readers seeking clinical detail:
Note on source limitations
All statements in this summary are drawn from the PubMed record excerpt provided. Where the excerpt omitted abstract text, numerical findings, or interpretive content, those details are stated as not reported; no outcome data or conclusions have been invented or inferred beyond what the source explicitly lists in its metadata.